Glenmark and Pfizer will co-market abrocitinib in India under the brand names JABRYUS and CIBINQO. Developed by Pfizer, abrocitinib has received marketing authorization for abrocitinib in adults with moderate-to-severe atopic dermatitis from the Central Drugs Standard Control Organization (CDSCO). It is also approved by the USFDA, European Medicines Agency (EMA), and other regulatory agencies.
NEW DELHI: Pfizer and Glenmark Pharma have joined hands to launch abrocitinib, a first-of-its-kind oral advanced systemic treatment for moderate-to-se.
Glenmark Pharmaceuticals and Ichnos Sciences have formed an alliance called Ichnos Glenmark Innovation (IGI) to accelerate cancer drug discovery. The alliance combines Glenmark s expertise in small molecules with Ichnos proficiency in novel biologics. They are developing therapy solutions for hematological malignancies and solid tumors, with three innovative oncology molecules currently in clinical trials.